



# Functionally Competent, PD-1<sup>+</sup> CD8<sup>+</sup> Trm Cells Populate the Brain Following Local Antigen Encounter

Amalie Skak Schøller, Loulieta Nazeraï, Jan Pravsgaard Christensen and Allan Randrup Thomsen\*

Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

## OPEN ACCESS

### Edited by:

Zsolt Illes,  
University of Southern Denmark,  
Denmark

### Reviewed by:

Klaas Van Gisbergen,  
Sanquin Diagnostic Services,  
Netherlands  
Andre Ortlieb Guerreiro Cacaïis,  
Karolinska Institutet (KI), Sweden

### \*Correspondence:

Allan Randrup Thomsen  
athomsen@sund.ku.dk

### Specialty section:

This article was submitted to  
Multiple Sclerosis and  
Neuroimmunology,  
a section of the journal  
Frontiers in Immunology

**Received:** 17 August 2020

**Accepted:** 17 December 2020

**Published:** 02 February 2021

### Citation:

Schøller AS, Nazeraï L, Christensen JP and Thomsen AR (2021) Functionally Competent, PD-1<sup>+</sup> CD8<sup>+</sup> Trm Cells Populate the Brain Following Local Antigen Encounter. *Front. Immunol.* 11:595707. doi: 10.3389/fimmu.2020.595707

Expression of programmed cell death-1 receptor (PD-1) has traditionally been linked to T-cell exhaustion, as signaling *via* PD-1 dampens the functionality of T-cells upon repetitive antigen exposures during chronic infections. However, recent findings pointing to the involvement of PD-1 both in T-cell survival and in restraining immunopathology, challenge the concept of PD-1 solely as marker for T-cell exhaustion. Tissue resident memory T cells (Trms) hold unique effector qualities, but within a delicate organ like the CNS, these protective abilities could potentially be harmful. In contrast to their counterparts in many other tissues, brain derived CD8<sup>+</sup> Trms have been found to uniformly and chronically express PD-1. In this study we utilized a recently established model system for generating CNS Trms in order to improve our understanding regarding the role of PD-1 expression by Trms inside the CNS. By intracerebral (i.c.) inoculation with a non-replicating adeno-viral vector, we induced a PD-1<sup>hi</sup> CD8<sup>+</sup> T cell memory population within the CNS. We found that PD-1 expression lowered the severity of clinical disease associated with the i.c. inoculation. Furthermore, high levels of PD-L1 expression were found on the infiltrating monocytes and macrophages as well as on the resident microglia, oligodendrocytes and astrocytes during the acute phase of the response. Additionally, we showed that the intensity of PD-1 expression correlates with local antigen encounter and found that PD-1 expression was associated with decreased CD8<sup>+</sup> T cell memory formation in the CNS despite an increased number of infiltrating CD8<sup>+</sup> T cells. Most importantly, our experiments revealed that despite expression of PD-1 and several additional markers linked to T-cell exhaustion, Tim-3, Lag-3 and CD39, the cells did not show signs of limited effector capacity. Collectively, these results endorse the increasing amount of evidence pointing to an immune-modifying role for PD-1 expression within the CNS, a mechanism we found to correlate with local antigen exposure.

**Keywords:** immune surveillance, CNS, tissue resident memory T cells, PD-1, adenovectors, viral infection

## INTRODUCTION

The CNS might be the target of acute as well as persistent viral infections. Despite the immune restriction of the CNS, such infections along with certain autoimmune diseases, e.g., multiple sclerosis (MS), represent unique challenges for effective pathogen and immune control. Following resolution of a local CNS infection a first line of protective immunity against recurrent or reactivated brain-infections is provided by a subset of local memory cells termed tissue-resident memory T cells (Trms) (1). It is widely known that during the course of CNS inflammation, the number of CNS infiltrating leukocytes dramatically increases (2, 3). This is the case during acute infections, but also a consequence of Trm re-activation e.g. upon a flare-up of a latent viral CNS infection (4–6). Therefore, despite the critical importance of generating immunological memory within the CNS, the unique qualities that Trms possess needs to be tightly controlled to limit immunopathology. Programmed cell death-1 receptor (PD-1) is known as a marker for T-cell exhaustion (7, 8). PD-1 expression has particularly been studied in models of chronic viral infections such as that following infection with the highly invasive clone 13 of lymphocytic choriomeningitis virus (LCMV), which is associated with a high and prolonged antigenic load (6, 8–11). CD8<sup>+</sup> T-cell exhaustion refers to a transformation of antigen-primed T-cells caused by repetitive TCR stimulation, leading to reduced effector capacity, including an impaired ability to produce pro-inflammatory cytokines such as IFN- $\gamma$  and TNF- $\alpha$  (12). Exhausted T cells additionally upregulate a range of markers for terminal differentiation as well as inhibitory receptors, the expression of which has been found to correlate with T-cell dysfunction. These include: CD39, 2B4, Tim-3, Lag-3, PD-1 as well as increased expression of Eomes (Eomesodermin) (7, 13–19). PD-L1 and PD-L2 are the ligands for PD-1 (20, 21). Engagement of PD-1 with these ligands initiates the recruitment of phosphatases, which inactivate kinase-cascades and ultimately inhibit the pathways required for effector T-cell function (22, 23). While PD-L2 is only expressed on antigen presenting cells, accumulating evidence has shown that PD-L1 is also expressed on a number of other cell types including astrocytes and glial cells during CNS infection (24, 25). Although microglia cells traditionally have been thought of as pro-inflammatory, their expression of PD-L1 have been shown to dampen immune-mediated tissue damage in studies on viral encephalitis and experimental autoimmune encephalomyelitis (EAE) (24–28). These findings challenges the use of PD-1 solely as a marker for T-cell exhaustion and indicates that initiating the PD-1:PD-L1 pathway could be a mechanism implemented to limit inadvertent effector T-cell functions to avoid tissue-damage in this non-regenerative organ (22, 24, 28–30). The PD-1 promoter (*Pdcd-1*) has been found to undergo epigenetic changes at the methylation level during the different developmental stages of CD8<sup>+</sup> T cells (31–33). A recent study by Wherry et al. demonstrated a disease specific relation for these epigenetic changes responsible for PD-1 expression (34). Accordingly, studies of chronic LCMV clone 13 infection

revealed that upon resolution of the infection, the *Pdcd-1* promoter remained un-methylated, whereas upon resolution of an acute infection with LCMV Armstrong, the *Pdcd-1* promoter was re-methylated causing downregulation of PD-1 (32, 33, 35). Based on these epigenetic studies, PD-1 involvement in the Trm differentiation program has been suggested (27, 36). In this study, we utilized our previously established model system for inducing CD8<sup>+</sup> T cell memory within the CNS (37). By intracranial inoculation (i.c.) with a non-replicating adeno-viral vector, we generated an immune response that mimics the response towards a non-lethal viral infection of the CNS. Due to the prolonged antigen exposure linked to the adenoviral infection (38, 39) we reasoned that this model could also serve as a model for certain CNS-directed autoimmune responses. In these settings, we asked whether PD-1 expression by brain localized CD8<sup>+</sup> T cells correlates with T-cell intrinsic exhaustion or primarily operates *in situ* to restrain inadvertent effector T cell functions that might lead to cell damage inside this delicate organ. Furthermore, we aimed at enlightening the mechanisms contributing to PD-1 expression. Our results suggest a prominent role of local antigen encounter for initial PD-1 upregulation by the CD8<sup>+</sup> T cells. Additionally, we show that PD-1 expression affected the severity of clinical disease associated with the i.c. inoculation as well as the memory potential of the CD8<sup>+</sup> T cells. Most interestingly, our experiments revealed that despite their seemingly exhausted phenotype, memory CD8<sup>+</sup> T cells maintained in the CNS did not show signs of T-cell intrinsic limitations in effector capacity.

## MATERIALS AND METHODS

### Mice

All mice used in this study were between 6–12 weeks old when entering the experiments. Mice were housed under controlled (specific pathogen free) conditions in individually ventilated cages in an ALAAC accredited animal facility at the Panum Institute (Copenhagen, Denmark). Wild -type (WT) female C57BL/6 (C57BL/6J BomTac, H-2<sup>b</sup>) mice were purchased from Taconic Farms (Ry, Denmark), and PD-1 KO mice (B6.Cg-Pdcd1tm1.1Shr/J) were obtained from the Jackson laboratories (Bar Harbour, MA, USA). Mice from outside sources were always rested for at least 1 week before entering an experiment. All procedures were approved by the national animal ethics committee (The Animal Experiment Inspectorate) and were conducted in accordance with national Danish guidelines.

### Recombinant Adenoviral Vectors

A replication deficient adenoviral vector encoding the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV) (AdLi-GP) was used to induce a potent CD8<sup>+</sup> T cell response. This human serotype 5 recombinant adenoviral (Ad5) vector with an E1-deleted and E3 inactivated region was constructed and purified as described in (40, 41).

## Immunization and Challenge With Live Virus (LCMV)

Mice were immunized by i.c. inoculation of  $2 \times 10^7$  pfu/30  $\mu$ L. For i.c. challenge of immunized mice, a volume 30  $\mu$ L containing a dose of  $10^3$  pfu LCMV Armstrong 53B was used; this dose is invariably lethal to unimmunized mice.

## In Vivo Depletion of CD8<sup>+</sup> T Cells

When mice were depleted from CD8<sup>+</sup> T cells, 200  $\mu$ g/300  $\mu$ L  $\alpha$ -CD8 mAb (YTS169.4) were administered i.p. one day prior to AdLi-GP i.c. inoculation (day -1). At day one (+1) and four (+4) after AdLi-GP i.c. inoculation, half the original dose  $\alpha$ -CD8 mAb (YTS169.4) (100  $\mu$ g/300  $\mu$ L) were administered i.p.  $\alpha$ -CD8 mAb (YTS169.4) were obtained from BioXcell.

## Blocking of T Cell Exit From the Lymph Nodes With FTY720

FTY720 was obtained from Sigma-Aldrich, and dissolved in water. For treatment, mice were allowed free access to drinking water containing FTY720 at a dose of 2.5  $\mu$ g/mL; treatment intervals varied and are described in the experiments.

## In Vivo 5-Ethynyl-2'-Deoxyuridine (EdU)-Labeling

95% EdU were obtained from Sigma-Aldrich, and dissolved in water. Mice were given EdU in their drinking water at a dose of 22.5  $\mu$ g/mL for varying periods of time as described in the experiments.

## Single Cell Preparation

Brains were aseptically removed after intracardial perfusion with 20 mL PBS. Mice were deeply anaesthetized during this process *via* intraperitoneal (i.p.) injection of avertin (2,2,2-tribromoethanol in 2-methyl-2-butanol, 250 mg/kg). Following the perfusion, brains were transferred to RPMI 1640 medium [supplemented with 1% L-glutamin, 1% penicillin, 1% streptomycin, 1% 2-mercaptoethanol (2-ME) and 10% fetal calf serum (FCS)]. To obtain single cell suspension brains were pressed through a 70- $\mu$ m nylon cell strainer. Single cell suspension was then centrifuged at 400 g for 10 min at 4°C. The remaining pellet was vortexed and lymphocytes were separated on a 37% Percoll gradient during 20 min centrifugation at 2800 g, 20°C. The supernatant was then carefully aspirated and the remaining pellet was vortexed and washed twice in RPMI 1640. An additional filtration through a 70- $\mu$ m cell strainer was performed and finally the cells were resuspended in FACS medium (PBS, 1% BSA, 0.1%  $N_3$ ).

Spleens were aseptically removed and transferred to Hanks Balanced Salt Solution (HBSS). Single-cell suspensions were obtained by pressing the spleens through a 70  $\mu$ m nylon cell strainer, followed by centrifugation and two washes in HBSS.

## Flow Cytometry Analysis

Approximately  $2-5 \times 10^6$  cells from the brain samples or  $2 \times 10^6$  splenocytes were transferred to wells of U-bottomed 96-well microtiter plates. For tetramer staining the cells were incubated

for 20 min (RT, in the dark) with 50  $\mu$ L FACS medium (PBS, 1% BSA, 0.1%  $N_3$ ) containing 10  $\mu$ L relevant fluorochrome labeled tetramers; these were kindly provided by S Buus and A Stryhn (this institute). To prevent unspecific binding cells were blocked with  $\alpha$ -CD16/32 and subsequently incubated for 20 min (4°C, in the dark) with 50  $\mu$ L brilliant violet staining buffer (Biolegend) containing conjugated antibodies (1:100) for the relevant cell-surface markers. Cells to be stained for intracellular granzyme B, T-bet or Eomes expression were permeabilized and stained according to the FoxP3 staining protocol from BD Biosciences. When analyzing the EdU incorporation cells were permeabilized and stained according to the Click-It™ Plus EdU Alexa Flour™ 647 Flow Cytometry Assay Kit from Invitrogen by Thermo Fisher Scientific. Cells were subsequently washed twice in wash media (PBS with 0.1%  $N_3$ ), resuspended in PBS and stored at 4°C until analysis. The general gating strategy regarding CNS derived cells is depicted in **Supplementary Figure 1**.

## Intracellular Cytokine Staining

When evaluating intracellular cytokine production, cells were first incubated for 5 hours (37°C, 5% CO<sub>2</sub>) in 200  $\mu$ L cell culture medium containing 50 IU/mL of IL-2 and 3  $\mu$ M monensin in the presence of 1  $\mu$ g/mL of the relevant peptides, LCMV GP<sub>33-41</sub> or GP<sub>276-286</sub>. As a control, samples without peptide stimulation were included. Following incubation, cells were centrifuged (2000 rpm, 3 min), and washed in FACS buffer containing monensin (PBS containing 1% BSA, 0.1%  $N_3$  and 3  $\mu$ M monensin). Then the cells were incubated for 20 min. (4°C, dark) with 50  $\mu$ L FACS/Monensin medium containing the relevant antibodies for surface staining (final dilution 1:100). Next, the cells were washed twice with PBS/monensin medium (3  $\mu$ M monensin in PBS) and fixed in 200  $\mu$ L 2% paraformaldehyde (PFA) for 15 min. (4°C, dark). Subsequently, cells were washed with FACS/monensin medium and incubated for 10 min. (20°C, dark) with 200  $\mu$ L Saponin medium (PBS containing 0.5% Saponin). Subsequently, cells were incubated for 20 min. (4°C, dark) in 50  $\mu$ L Saponin medium containing the relevant intracellular antibodies (1:100), and then washed twice with Saponin medium. Finally, the cells were resuspended in PBS and stored at 4°C until flow cytometry analysis was performed.

The samples were analyzed using a FACS—Fortessa 3—or 5 cytometer (BD Biosciences) and subsequently gated and analyzed in FlowJo software version 10 (TreeStar).

## Reagents for Flow Cytometry

The following fluorochrome-conjugated Abs, purchased from Biolegend, eBiosciences or BD Bioscience as anti-mouse antibodies, were used for cell surface staining:  $\alpha$ -CD8,  $\alpha$ -CD11b,  $\alpha$ -CD45.2,  $\alpha$ -CD103,  $\alpha$ -CD69,  $\alpha$ -PD-1,  $\alpha$ -PD-L1,  $\alpha$ -CD127,  $\alpha$ -CD43,  $\alpha$ -CD39,  $\alpha$ -Tim-3,  $\alpha$ -Lag-3,  $\alpha$ -CD244.2 (2B4),  $\alpha$ -O4,  $\alpha$ -ASCA2, and  $\alpha$ -KLRG1. When staining for intracellular markers, the following fluorochrome-conjugated monoclonal antibodies were used:  $\alpha$ -IFN- $\gamma$ ,  $\alpha$ -IL-2,  $\alpha$ -TNF- $\alpha$ , granzyme B, T-bet or Eomes. Incorporation of EdU was evaluated using the EdU Alexa Flour™ 647 antibody Click-It™ from Invitrogen by Thermo Fisher Scientific.

## Statistical Evaluation

Analyses was performed using GraphPad Prism software (version 7). Quantitative results were compared using a nonparametric Mann-Whitney *U*-test; a *p* value of <0.05 was considered evidence of a statistically significant difference and was visualized by an asterix (\*).


## RESULTS

### CD8<sup>+</sup> Trm Cells in the CNS Undergo Local Homeostatic Proliferation

In a previous study we showed that i.c. inoculation of a non-replicating adenoviral vector expressing a non-self antigen induced a stable population of antigen-specific CD8<sup>+</sup> Trm cells inside the CNS (37). However, although these cells seemed to undergo prolonged proliferation based on expression of Ki-67, we wanted to confirm active cell division using a more direct technique and also to determine whether there was ongoing local proliferation.

Therefore, to study how the Trm population is sustained long-term, the proliferative activity of the CD8<sup>+</sup> T cell population in the CNS was analyzed by an *in vivo* EdU-incorporation assay. Two groups of C57BL/6 mice were inoculated intracerebrally (i.c.) with 2x10<sup>7</sup> pfu Adli-GP, and brains were harvested at 7 and 60 days post inoculation (p.i.). Half of the mice were administered EdU in their drinking water for four or eight days, respectively, prior to cell extraction. The CD8<sup>+</sup> - and antigen specific CD8<sup>+</sup> T cells extracted from the CNS showed clear EdU incorporation, particularly during the effector-phase of the response (day 7 p.i.), but significant EdU incorporation was also found during the memory-phase (day 60 p.i.) (Figure 1).


To investigate whether the observed EdU incorporation during the memory phase reflected local CD8<sup>+</sup> T-cell proliferation and not ongoing replenishment by circulating T cells recently derived from cells proliferating in the secondary lymphoid organs, FTY720 was added during the period of EdU incorporation. FTY720 has previously been found to inhibit the recruitment of activated CD8<sup>+</sup> T cells to the site of antigen challenge (36, 42, 43). Two groups of mice were inoculated i.c. with Adli-GP and 10 days prior to cell extraction half of the mice



were administered FTY720 in their drinking water. Eight days pre cell extraction, all mice were administered EdU in their drinking water or in the FTY720/drinking water mixture. The number of CD8<sup>+</sup> T cells and antigen specific CD8<sup>+</sup> T cells were determined for both groups. Slightly fewer CD8<sup>+</sup> T cells were recovered from the brain after FTY720 treatment (**Figure 2A**). However, despite inhibition of T-cell recruitment, the percentage of EdU incorporating CD8<sup>+</sup> T cells extracted from the CNS was similar between the two groups (**Figure 2B**), indicating that the sustained proliferative ability of the CD8<sup>+</sup> T cells in CNS did not simply reflect the arrival of cells that have recently divided in lymphoid organs. These results indicate that the CNS memory CD8<sup>+</sup> T cell population retains the capacity to undergo local homeostatic proliferation.

## CD8<sup>+</sup> Trm Cells From CNS Express a Range of Inhibitory Receptors Correlating With Signs of Recent Activation

Pertaining to the persistence of CD8<sup>+</sup> memory T cells in the CNS, we have found that at least half of the CNS infiltrating CD8<sup>+</sup> T cells display a so called memory precursor phenotype with expression of CD127, but not KLRG1 (1, 37). However, the expression of CD127 on part of the CD8<sup>+</sup> T cells inside the CNS was reduced compared to the expression on their splenic counterparts (37). In view of reports suggesting that Trms isolated from the brains of mice with certain chronic neuroinfections express elevated levels of PD-1 (28, 33), we decided to investigate whether the reduced level of CD127 expression could be linked to PD-1 expression, and whether




**FIGURE 2** | CD8<sup>+</sup> Trm cells in the CNS undergo local homeostatic proliferation. Two groups of mice were inoculated i.c. with Adli-GP and 10 days prior to brain extraction half of the mice were administered FTY720 in their drinking water. Eight days before brain extraction, all mice were administered EdU in their drinking water or in the FTY720/drinking water mixture, respectively. **(A)** The number of CNS infiltrating CD8<sup>+</sup> T cells and antigen specific (tetramer<sup>+</sup>) CD8<sup>+</sup> T cells were measured for both groups. Each dot represents an individual. Bars represent median. P > 0.05 illustrated by \* **(B)** The percentage of EdU positive CD8<sup>+</sup> and antigen specific CD8<sup>+</sup> T cells were analyzed day 80 post i.c. to compare EdU incorporation in the presence of FTY720 or when recruitments were allowed. Percentages and representative plots of 4–5/group are shown. Results are representative of 2 experiments.

PD-1 expression could be essential in modulating the local response and memory generation. Mice were inoculated with Adli-GP i.c., and brains and spleens were extracted on day 40. p.i. The expression of CD127 and PD-1 was analyzed for CD8<sup>+</sup> T cells in the brain and spleen and for the antigen specific CD8<sup>+</sup> T cells recruited to the CNS. Interestingly, CD8<sup>+</sup> T cells isolated from the brain showed a markedly elevated expression of PD-1 compared to their counterparts in the spleen. Furthermore, cells with intermediate expression of PD-1 tended to express higher levels of CD127 (Figure 3A), this pattern was maintained over time (data not shown). Recent studies have suggested that Trms may express other phenotypic markers normally associated with exhaustion (33, 44–46). In order to carry out an in-depth analysis of the CNS localized CD8<sup>+</sup> T cells with regard to markers of functional dysfunction, mice were inoculated with Adli-GP i.c. On day 12, 63 and 105 p.i., brains and spleens were extracted,

and surface expression of 2B4, CD39, Lag-3 and Tim-3 for the total number of CD8<sup>+</sup> T cells were analyzed. Unlike 2B4, which we did not find to be expressed at any time-point, we observed that the CD8<sup>+</sup> T cells from CNS also expressed CD39, as well as Lag-3 and Tim-3 (Figure 3B). Expression of Lag-3 and Tim-3 was evident throughout the observation period, although we noted a trend toward decreasing expression with time (Figure 3B). In contrast, CD39 expression did not decline markedly with time (Figure 3B).

We reasoned that the observed decline in Lag-3 and Tim-3 expression might reflect a decrease in the state of activation during the analyzed time-period. Consequently, we decided to follow the percentage of CD8<sup>+</sup> T cells expressing CD43, as CD43 has been associated with recent CD8<sup>+</sup> T-cell activation and proliferation (47, 48). For that reason, mice were inoculated with Adli-GP i.c. and day 12, 63 and 105 p.i. respectively, brains




**FIGURE 3** | Expression of inhibitory receptors on CD8<sup>+</sup> T<sub>RM</sub> cells correlate with signs of recent activation. Wild type C57BL/6 mice were inoculated with Adli-GP i.c. (A) Representative plots of showing PD-1 and CD127 expression by CD8<sup>+</sup> splenocytes, total CD8<sup>+</sup> and the antigen specific (tetramer<sup>+</sup>) CD8<sup>+</sup> T cells from CNS. Splenocytes are included for comparison. Results are representative of analyses of groups of mice carried out between 12 and 103 days after inoculation. (B) Representative histograms of 5 mice/group showing the expression of the inhibitory receptors 2B4, CD39, Lag-3 and Tim-3 by CNS infiltrating CD8<sup>+</sup> T cells at twelve, 63 and 105 days post i.c. FMOs are included as controls for background. Medians of mean fluorescence intensities and ranges of expression of each marker for groups of 4–5 mice are depicted. Results are representative of 2–3 experiments for each time point. (C) Percentage of CD43<sup>high</sup> CD8<sup>+</sup> T cells as a function of time after virus inoculation. Columns represent medians +/- ranges of 4–5 mice.

were extracted and the expression of CD43 was analyzed. In agreement with our assumption, we found a decrease in the percentage of CD43 expressing CD8<sup>+</sup> T cells from around 80% on day 12 to about 40% day 105 p.i. (**Figure 3C**).

## Recruited Immune—and Local Parenchymal Cells Express Increases Levels of PD-L1 During Acute CNS Inflammation but Declines Over Time

We next wanted to investigate whether PD-1 expression could affect the functionality of the T cells inside the CNS. PD-1 mediated inhibition would only work, if relevant ligands were expressed on cells potentially interacting with the CD8<sup>+</sup> T cells. Consequently, we wanted to investigate whether local CNS – and/or infiltrating cells expressed PD-L1. Mice were inoculated i.c. with Adli-GP and

brains were harvested on day 11 and 60 p.i. Based on the expression of the adhesion molecule CD11b, the leukocyte marker CD45 as well as ACSA-2 and O4, markers for astrocytes and oligodendrocytes, respectively (49, 50), microglia, astrocytes and oligodendrocytes as well as the infiltrating neutrophils/monocytes/macrophages were gated (**Figure 4A**). These subsets were then analyzed for expression of PD-L1. Interestingly, during the effector-phase of the T-cell response, all of the analyzed cell types expressed PD-L1 at an increased level compared to control animals (**Figure 4B**). It should also be noted that PD-L1 expression by local and recruited innate immune cells was markedly higher than what was found for astrocytes and oligodendrocytes, where only a portion of the total population expressed PD-L1 (**Figure 4B**). At 60 days p.i. PD-L1 expression was noted mainly on infiltrating monocytes/macrophages, and at 105 days p.i. expression on all cell population seemed to be further




**FIGURE 4 |** Recruited immune and local CNS cells express PD-L1 during acute CNS inflammation, but expression declines over time. Following inoculation with Adli-GP i.c., infiltrating neutrophils, monocytes and macrophages as well microglial cells were categorized based on the expression of CD45.2 and CD11b. The CD45<sup>low</sup>CD11b<sup>low</sup> cells were further subdivided into O4<sup>+</sup> oligodendrocytes and ASCA2<sup>+</sup> astrocytes. (**A**) Representative plots of 4–5 mice at each time point, showing the gating of the three major cell-subsets for naïve mice and mice taken at two time-points post inoculation. For representative plot showing the subdivision into oligodendrocytes and astrocytes, please see **Supplementary Figure 2**. (**B**) Representative histogram of PD-L1 expression by the above mentioned cell subsets at day 0 (naïve mice), 11, 60 and 105, respectively. FMOs are shown in all histograms to indicate background. Medians of mean fluorescence intensities and ranges of PD-L1 expression for groups of 4–5 mice are included.

normalized (Figure 4B). These data supported a possible role for PD-L1:PD-1 interaction in regulating the induced, acute inflammatory activity inside the CNS.

## Local Antigen Encounter Increases PD-1 Expression by CD8<sup>+</sup> Trm Cells in CNS

Next we wanted to investigate the association between local antigen encounter versus bystander inflammation as key factors for inducing PD-1 expression by CNS localized CD8<sup>+</sup> T cells. Consequently, three groups of C57BL/6 mice were inoculated with Adli-GP in the footpad (f.p.). This inoculation was combined with an i.c. inoculation of either 30  $\mu$ L PBS for control, the same construct or an adeno-vector construct encoding the gene for murine IFN- $\gamma$ , which cause the infected

cells to produce this pro-inflammatory cytokine (51). Brains and spleens were harvested day 12 p.i. The expression of PD-1 on antigen specific CD8<sup>+</sup> T cells was analyzed. In accordance with our previous findings, i.c. inoculation with the antigen expressing adenoviral-vector resulted in the establishment of a robust antigen-specific CD8<sup>+</sup> T cell population in the CNS (37), which was dominated by cells expressing high levels of PD-1 (Figure 5A). However, when we analyzed the more limited number of antigen specific CD8<sup>+</sup> T cells recruited non-specifically by IFN- $\gamma$ , expression of PD-1 was also up-regulated, albeit to a lesser degree (Figures 5A, B). Thus, the MFI value for PD-1 expression was significantly higher when antigen was presented locally compared to the situation where only unspecific inflammation occurred (Figure 5C).




**FIGURE 5** | Local antigen encounter increases PD-1 expression on CD8<sup>+</sup> Trm cells. Three groups of C57BL/6 mice were inoculated with Adli-GP in the footpad (f.p.), combined with i.c. inoculation of either PBS for control, the same construct or an adeno-vector construct encoding the gene for murine IFN- $\gamma$  expression. Day 12 post i.c. inoculation, brains were extracted and the expression of PD-1 was analyzed. **(A)** Representative plots of 5 mice showing PD-1 expression on total CD8<sup>+</sup> T cells and antigen specific (tetramer<sup>+</sup>) CD8<sup>+</sup> T cells respectively. Cut-offs are based on PD-1 FMOs for background expression in the brain. **(B)** Representative histograms of 5 mice illustrating PD-1 expression on antigen specific CD8<sup>+</sup> T cells harvested from the brains of Adli-GP f.p. vaccinated mice combined with either Adli-GP or Ad-IFN- $\gamma$  i.c. inoculation. **(C)** Mean fluorescent intensity (MFI) for PD-1 expression on antigen specific CD8<sup>+</sup> T cells isolated from brains of Adli-GP f.p. vaccinated mice combined with either Adli-GP or Ad-IFN- $\gamma$  i.c. inoculation. Background reflects MFI measured in PD-1 FMO from the brain. Each dot represents an individual, bars represents median.  $P > 0.05$  illustrated by \*. Results are representative of 2 experiments.

## PD-1 Modifies the T Cell-Mediated Immunopathology Caused by Intracerebral Inoculation of Adli-GP

As robust T-cell infiltration to the CNS is a key aspect of our model-system, we speculated whether this could result in T-cell mediated neuropathology. Therefore, three groups of mice were inoculated i.c. with Adli-GP. Two days prior to i.c. inoculation two of the groups were administered FTY720 in their drinking water. One group of mice was, in addition to the FTY720 treatment, depleted of CD8<sup>+</sup> T cells by injections with CD8<sup>+</sup> specific antibodies. Antibody injections were performed one day before i.c. inoculation and again three days post i.c. No signs of immunopathology were observed in the group, in which the mice were both depleted of CD8<sup>+</sup> T cells and blocked for CD8<sup>+</sup> T-cell recruitment to the CNS (**Figure 6A**). However, both groups of mice without any CD8<sup>+</sup> T-cell depletion showed a significant decrease in bodyweight compared to mice depleted of CD8<sup>+</sup> T cells (**Figure 6A**). On its own, the treatment with FTY720 did not cause a complete block in CD8<sup>+</sup> T cell migration to the CNS, however, the treatment did reduce the early recruitment of CD8<sup>+</sup> T cells by a factor of three to four fold (**Figure 6B**). This indicates that although the observed clinical disease is CD8<sup>+</sup> T-cell

dependent, there is no direct correlation between CD8<sup>+</sup> T-cell numbers inside the CNS and the severity of the observed disease.

To analyze whether PD-1 expression modifies the severity of clinical disease following Adli-GP i.c. inoculation, WT and PD-1 KO mice were inoculated i.c. with Adli-GP. In addition, a group of WT mice inoculated with PBS was included as a control for the pathology induced by the inoculation trauma. Body weights of all mice were measured during a period from zero to 11 days p.i. In accordance with our previous findings of local antigen expression as an essential driver of CNS T-cell infiltration (37), no signs of clinical disease were observed in PBS inoculated WT mice (**Figure 6C**). In contrast, both groups of Adli-GP inoculated mice showed a significant weight loss compared to the PBS control group (**Figure 6C**). Most interestingly, despite the fact that both groups of Adli-GP inoculated mice show signs of recovery by the end of the observation period, the group of Adli-GP vaccinated PD-1 KO mice lost significantly more body weight during the observation period, compared to WT Adli-GP inoculated mice. This is clearly seen, if area under the curve (AUC) is calculated for both groups (**Figure 6C**). Based on these clinical data, we conclude that PD-1 expression on CD8<sup>+</sup> T cells helps dampening the severity of the acute immunopathology



caused by Adli-GP induced local antigen expression within the CNS.

## PD-1 Expression Significantly Impact Both Numbers of Initially Recruited CD8<sup>+</sup> T Cells as Well as Memory Cell Differentiation


The above findings led us to speculate whether PD-1 expression had any direct effects on the CD8<sup>+</sup> T-cell recruitment to the CNS. For that reason, numbers of CNS infiltrating antigen specific CD8<sup>+</sup> T cells was analyzed 7 and 40 days post i.c. inoculation in WT and PD-1 KO mice inoculated with  $2 \times 10^7$  pfu Adli-GP. Interestingly, although the pathology was found to be more severe in PD-1 KO mice, significantly fewer antigen specific CD8<sup>+</sup> T cells were recovered from the CNS of these mice during the effector phase, compared to WT mice (Figure 7A). In the memory phase analyzed at day 40 p.i., a significant difference in numbers of local antigen specific CD8<sup>+</sup> T cells was no longer observed (Figure 7A).

Recent studies have pointed to a possible role of PD-1 in Trm differentiation (27, 36). For that reason, we decided also to analyze whether PD-1 expression affected the differentiation of recruited CD8<sup>+</sup> T cell into canonical Trm cells. More specifically, we investigated whether PD-1 expression affected the expression of some of the cardinal markers for Trms, namely the expression of CD127 and CD103 (27, 52). As previously, WT and PD-1 KO

mice were inoculated i.c. with Adli-GP and brains were harvested day 7 and 40 p.i. and antigen specific CD8<sup>+</sup> T cells were analyzed for the expression of CD127 and CD103. At the early time-point, no difference was observed in neither the number nor percentage of CD8<sup>+</sup> T cells expressing CD127 (Figure 7B). However, when comparing PD-1 KO and WT mice in the memory phase (day 40 p.i.), the picture was different. Thus, while absolute numbers of subtypes of CD8<sup>+</sup> T cells were mostly of similar magnitude (see Supplementary Figure 3), the distribution of cells within the defined subsets was different: the percentage of cells positive for CD127 was significantly increased in PD-1 KO mice compared to WT mice (Figure 7B), as was the percentage of CD103 positive CD8<sup>+</sup> T cells (Figure 7C). Therefore, unlike published data, these data indicate that PD-1 expression impairs the full development of canonical Trms in the CNS.

## Analysis of Transcriptional Factors Eomes and T-Bet in CD8<sup>+</sup> Trm Cells Reveals No Signs of Exhaustion

Based on the above observations, we went on to investigate whether PD-1 expression had any impact on the functionality of the induced CD8<sup>+</sup> T cell population in the long-term. In particular we wanted to investigate whether the CNS induced CD8<sup>+</sup> T cell population showed signs of exhaustion upon PD-1 expression. As a first thing we analyzed the transcriptional profile of the local CD8<sup>+</sup> T cells. The relative levels of expression of the




transcription factors T-bet and Eomes is an important indicator of the differentiation stage of memory CD8<sup>+</sup> T cells (19, 53, 54). For that reason, the expression level of these specific transcription factors were analyzed for the CNS CD8<sup>+</sup> memory T-cell population induced upon Adli-GP i.c. inoculation. C57BL/6 mice were inoculated i.c. with Adli-GP and 11 and 60 days p.i., brains were extracted and CD8<sup>+</sup> T cells were analyzed for the intracellular expression of T-bet and Eomes. The expression of Eomes, which is typically highly expressed in exhausted cells, was marginally elevated during both effector - and memory phase of the immune response (day 11 and 60, respectively) (**Figure 8**). In contrast, T-bet expression, which is expressed at intermediate levels by Trm cells, was found to be expressed at both time-points (**Figure 8**). Notably, analysis of co-expression of these transcription factors did (data not shown) not reveal the dichotomy of memory CD8<sup>+</sup> T cell subset typical of an exhausted population (19), instead the transcriptional profile of the Adli-GP induced CD8<sup>+</sup> T cell population within the CNS

matches the transcriptional profile described for Trms in several peripheral organs (55).

## CNS CD8<sup>+</sup> Memory T Cells Are Fully Functional

Next, we wanted to investigate whether the memory CD8<sup>+</sup> T cells generated upon i.c. inoculation showed any evidence of being functionally exhausted. To this end, we analyzed the cytokine-producing abilities of identical memory CD8<sup>+</sup> T cell populations recovered from either spleen or CNS. Forty days post i.c. inoculation with Adli-GP, brain and spleen derived CD8<sup>+</sup> T cells were harvested and restimulated *in vitro* with peptides representing two of the major epitopes encoded in the adeoviral-construct, namely LCMV GP<sub>33-41</sub> and GP<sub>276-281</sub>. A sample of both brain and spleen cells were left unstimulated to determine background expression. The number of CNS derived CD8<sup>+</sup> T cells producing IFN- $\gamma$ , IFN- $\gamma$  and TNF- $\alpha$  – or IL-2 were enumerated as shown in **Figure 8A**. Although the response




varied in accordance with the immunodominance hierarchy, the production of all three cytokines was significantly increased compared to the unstimulated sample (**Figure 9A**). In particular, the production of IFN- $\gamma$  and TNF- $\alpha$  was markedly increased upon *in vitro* recognition of the cognate antigen (**Figure 9A**). To compare per cell capacity for cytokine production, mean fluorescence intensity (MFI) of the IFN- $\gamma$  signal was determined for antigen specific cells harvested not only from the CNS, but also for cells with the same antigen specificity in the spleen of the same mice. Interestingly, when we compared the MFI values for the PD-1<sup>+</sup> neuro-inflammatory CD8<sup>+</sup> T cells with their PD-1<sup>-</sup> counterparts in the spleen, a significantly higher average MFI value was noted for the CNS derived population (**Figures 9B, C**). Consequently, these data strongly indicate, that the CNS localized memory CD8<sup>+</sup> T-cell population intrinsically is not functionally impaired despite their PD-1<sup>+</sup> phenotype.


Finally, to study the responsiveness of the CNS Trms *in situ*, we set up an additional experiment where we evaluated the capacity of the cells to become reactivated during local antigen challenge. To assure that the measured response reflected the response of the local cells, mice were administered FTY720 in their drinking water 43 days after induction of a Trm population using AdLi-GP *i.c.* inoculation. Two days later, part of the mice was challenged *i.c.* with an otherwise lethal dose of LCMV

Armstrong. At three days post-challenge brains were harvested from all animals and the expression of granzyme B as well as CD11b was used to gauge the *in vivo* response of the antigen specific CD8<sup>+</sup> T cells. A significantly increased expression of granzyme B was induced following challenge with LCMV Armstrong. In a previous study, we have clearly correlated the expression of CD11b to the activation state of the CD8<sup>+</sup> T cells, and matching the increase in granzyme B expression, we also observed an increased CD11b expression following challenge with LCMV (**Figure 10A**) (56). We also looked for increased incorporation of EdU, however, no increase was observed for the challenged mice (**Figure 10B**). This probably indicates that the re-infection never reached a level sufficient to drive a proliferative response. Collectively, the above data strongly indicate that the antigen specific CD8<sup>+</sup> T cells located within the CNS are functionally capable of responding upon antigen stimulation, not only *in vitro*, but also *in vivo*.

## DISCUSSION

Trms present inside the CNS constitute a population of primed sentinel cells, which provides the CNS with long-term protective immunity against recurrent or reactivated brain-infections. However, to limit immunopathology, the efficient effector





**FIGURE 10** | *In situ* functional capacity of the PD-1 positive CD8<sup>+</sup> T cell in the memory stage. C57BL/6 mice were inoculated with Adli-GP i.c. and FTY720 was administered to all mice day 43 post inoculation. *In vivo* challenge was performed for half of the mice by i.c. infection with LCMV Armstrong two days later (day 45 p.i.). Antigen specific (tetramer<sup>+</sup>) CD8<sup>+</sup> T cells were analyzed. **(A)** Representative histograms of 5 mice showing the content of Granzyme B and the expression of CD11b for challenged and unchallenged mice, respectively. These data are also graphically presented as the percentage of antigen specific (tetramer<sup>+</sup>) CD8<sup>+</sup> T cells positive for Granzyme B and CD11b. **(B)** Three groups of C57BL/6 mice were administered FTY720 43 days post i.c. inoculation with Adli-GP. Group A and B were administered EdU and group C was left as a negative control for EdU incorporation. Group B and C were challenged i.c. with LCMV Armstrong at day 45 p.i. The percentage of CD8<sup>+</sup> and antigen specific CD8<sup>+</sup> T cells positive for EdU are shown. Each dot represents an individual. Columns represent median.  $P < 0.05$  illustrated by \*.

mechanisms held by this memory subset needs to be tightly controlled. Trms and their effector mechanisms have been studied in various organs (1, 4, 57–59). Despite that, our general knowledge about the mechanisms involved in restricting these functions within a non-regenerative tissue like the brain, is limited.

In this present study, we provide evidence that point to an immune modulating role of PD-1 expression by brain infiltrating CD8<sup>+</sup> T cells. This analysis was conducted utilizing a recently established *in vivo* model for generating Trms within the CNS (37). By intracerebral inoculation with a non-replicating adenoviral vector we were able to induce long-lasting CD8<sup>+</sup> T cell memory within the CNS. In accordance with studies of brain Trms cells carried out in the context of chronic viral infections, we found sustained PD-1 expression by the CNS infiltrating CD8<sup>+</sup> T cells (28, 33). An impact of PD-1 on effector capacity can, however, only be relevant if the involved cells encounter their relevant ligand. The high number of IFN- $\gamma$  producing effector CD8<sup>+</sup> T cells recruited to the CNS would likely stimulate PD-L1 upregulation, as IFN- $\gamma$  has been found to be a potent inducer of PD-L1 expression (22, 29). However, expression of PD-L1 by the different cell subsets in the

inflamed CNS, seem to vary dependent on the source and duration of infection (24, 29, 30). Our findings of PD-L1 upregulation on various infiltrating and resident CNS cells are in agreement with the observations found for PD-L1 expression on CNS cells during mouse polyomavirus (MuPyV) infection (22). Similar to the situation predicted in our model system, MuPyV infection results in repetitive exposure of low-level of antigen. This was shown to result in PD-L1 expression on infiltrating monocytes, microglia and astrocytes, whereas PD-L1 expression on oligodendrocytes was not detected (22). Accordingly, we found markedly elevated PD-L1 expression by the recruited innate immune cells compared to the expression of PD-L1 on the resident CNS cells. The observed decrease in PD-L1 expression with time likely reflects a decrease in the stimulation of the recruited T cells as the infection subsides (indicated by the decreasing level of CD43 expression (**Figure 3C**), see further below), resulting in reduced levels of IFN- $\gamma$ . It should be noted, however, that although the expression of PD-L1 decreased with time, distinct expression was maintained by some cell types at least until day 60 post i.c. permitting some PD-1:PD-L1 interaction also long-term.

In accordance with some previous studies of Trm cells present inside the CNS, we found the recruited CD8<sup>+</sup> T cells to express additional inhibitory receptors linked to T-cell exhaustion (28, 60). As with PD-L1, the expression of Tim-3 and Lag-3 decreased with time. This was found to correlate with decreased signs of recent CD8<sup>+</sup> T-cell activation and proliferation, as indicated by a decrease in the percentage of CD8<sup>+</sup> T cells expressing CD43 (48). Although our results do not directly evaluate the link between antigenic load and receptor expression, the decrease in CD43 likely reflects a decrease in antigen expression (47), indicating a correlation between local antigen and sustained expression of inhibitory markers expressed by the CD8<sup>+</sup> T cells. We, and others have previous shown local antigen expression to be pivotal in upregulation of CD103 by brain localized Trms (4, 37, 45). This is, however, not the case in several other tissues (52, 61, 62), which led us to wonder whether antigen or a local inflammatory environment would be key inducer of PD-1 expression by memory CD8<sup>+</sup> T cells localized in the brain. Although we did find clear PD-1 expression in the context of bystander inflammation, our data points to a clear relation between local antigen encounter and level of PD-1 expression. The PD-1 expression was more pronounced in the presence of local antigen than as a result of bystander inflammation, indicating that although factors in the CNS environment seem to drive PD-1 expression, TCR signaling within the CNS critically increase PD-1 expression by the local CD8<sup>+</sup> T cells. In accordance with our findings regarding prolonged PD-1 expression, a recent study of Shwetank et al. showed that despite equivalent viral loads in brain and spleen, the *Pdcd1* promoter remained more extensively demethylated in brain Trms, suggesting that the brain milieu somehow favors PD-1 expression (33). Interestingly, similar to the PD-1 receptor, CD39 expression did not decrease over time. Although several studies have reported CD39 as a marker related to T-cell exhaustion and death, CD39 has also been found to possess nuclease activity and thereby the ability to generate extracellular adenosine through ATP hydrolysis (63, 64). ATP concentrations are high in inflamed tissue, like the CNS in our model settings, and CD39 could likely convert this high concentration of ATP into adenosine. Adenosine signaling have been found to inhibit the TCR mediated activation of the Akt-pathway, which otherwise contribute to T cell differentiation (65–67). Thus, CD39 likely initiates Akt-inhibition in the T cell by generating adenosine and *via* Akt-inhibition contribute to regulating the fate of the T cell by controlling the differentiation into SLEC or MPEC (68). Accordingly, this Akt-inhibition have been associated with enhanced formation of long lived memory CD8<sup>+</sup> T cells and enhanced T cell persistence (65, 66). Furthermore, to underline the important role of CD39 expression as an immune regulatory receptor, T cell activation in the presence of an agonist for the adenosine receptor, have been reported to generate Tregs with stronger immune regulatory potential (69). Conversely, deficiency in the receptor responsive to adenosine was reported to result in reduced CD127 (70) which are in line with findings showing

that adenosine signaling are necessary for CD127 expression and survival of long-lived memory CD8<sup>+</sup> T cell (70, 71). When we, in a previous study analyzed the expression of CD127, we found that the portion of CD8<sup>+</sup> T cells showing moderate expression of CD127 was higher in the CNS than in the spleen (37). Both the expression of CD127 and PD-1 by brain resident Trms have been linked to prolonged or chronic antigen expression (27). However, when we in this present study, correlated CD127 expression with PD-1, we found a reciprocal expression pattern of PD-1 and CD127. This let us to speculate whether PD-1 expression could influence memory differentiation. Conflicting results have been found with regard to the correlation between PD-1 expression and the canonical Trm markers CD127 and CD103 (22, 27). Reduced expression of CD127 have been found in both PD-1 and PD-L1 KO mice, and have been linked to prolonged effector like T-cell responses in the CNS of mice chronically infected with murine cytomegalovirus (MCMV) (27). In contrast, we found a significant decrease in the percentage of of antigen specific memory CD8 T cells expressing either CD127 or CD103 in WT mice compared to those from matched PD-1 KO mice. Rather than indicating a prolonged effector T-cell response, we believe these findings suggest that PD-1 expression could influence not only T-cell effector capacity, but also impact the differentiation of the memory CD8<sup>+</sup> T cell population within the CNS. Together with the prolonged expression of CD39, we believe these markers could act as counterparts for balancing the generation of long-lived memory CD8<sup>+</sup> T cells within the CNS.

When investigating the clinical consequences related to intracranial inoculation of Adli-GP, we observed that PD-1 expression by the CD8<sup>+</sup> T cells helps dampening the severity of the acute immunopathology generated upon Adli-GP induced, local antigen expression within the CNS. A lower number of antigen specific CD8<sup>+</sup> T cells were recruited to the CNS of PD-1 KO mice, yet these mice experienced a slightly more severe clinical course than matched WT mice. However, although the observed immunopathology was clearly associated with CD8<sup>+</sup> T-cell recruitment, we found no direct correlation between CD8<sup>+</sup> T-cell numbers and clinical severity. This observation was also made comparing the clinical course for untreated WT mice versus WT mice treated with FTY720. Based on these data, it is tempting to conclude that although recruited in higher numbers, antigen specific WT CD8<sup>+</sup> T cells cause less disease than cells lacking PD-1 expression, indicating that the activation state of the infiltrating CD8<sup>+</sup> T cells, rather than their absolute numbers is critical in mediating neuropathology.

The most striking finding obtained during this study was obtained when we analyzed the functionality of the PD-1 positive CD8<sup>+</sup> T cells in CNS. In line with several studies showing that CD8<sup>+</sup> T cells with a restrained phenotype retain the ability to contribute to viral control (13, 19, 46, 72), we found, that despite the exhausted phenotype of CNS resident CD8<sup>+</sup> T cells, these cells were nevertheless able to produce a potent cytokine response upon restimulation *ex vivo*. Indeed, the potential for cytokine expression measured in terms of the per cell expression of intracellular cytokine storage was significantly higher for PD-

1<sup>+</sup> antigen specific CD8<sup>+</sup> T cells from CNS than for PD-1<sup>-</sup> splenic memory cells of the same specificity. The additional results obtained when analyzing the transcriptional profile of the CD8<sup>+</sup> T cells maintained in the CNS, also points to a functional memory subset, as we found a T-bet<sup>int</sup> Eomes<sup>low</sup> phenotype. This does not match what others have found for populations of exhausted CD8<sup>+</sup> T cells (19), but rather fits the transcriptional profile found for Trms in several peripheral organs (55, 73). Additionally, our experiments assessing the capacity of the CD8<sup>+</sup> T cells to respond to direct intracerebral challenge with LCMV Armstrong revealed that re-infection drove a distinct upregulation of CD11b and led to increased intracellular expression of granzyme B in the antigen specific CD8<sup>+</sup> T cells. Although we did not observe increased local proliferation as a response to rechallenge, we did find that the bona fide CNS CD8<sup>+</sup> Trm cells retained the capacity to undergo local homeostatic proliferation to maintain the population despite being PD-1 positive.

Taken together this study contributes with insight into the mechanisms involved in maintaining and regulating immune responses within the CNS. Our results revealed a functionally capable memory CD8<sup>+</sup> T cells population inside the CNS, despite expression of PD-1. This population is maintained, at least in part, through local homeostatic proliferation. That is not to say, that PD-1 does not exert any relevant immune-regulatory role inside CNS. First of all, during the acute phase of the response, when there is active inflammation, the severity of this is modulated by PD-1:PD-L1 interaction. Second, expression of PD-1 significantly modifies the relative phenotypic composition of the memory CD8<sup>+</sup> T cells found following establishment of a local Trm population. Based on these results we suggest that rather than serving as a marker of epigenetically modified cells, PD-1 on Trms in the CNS represent a fast switch to rapidly modulate T cell induced inflammation in a highly vulnerable organ. Hopefully a better understanding of immune regulation inside CNS will be of benefit in the search for new targets of treatment for diseases like acute disseminated encephalomyelitis (ADEM) and MS.

## REFERENCES

- MacKay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, et al. The developmental pathway for CD103<sup>+</sup> CD8<sup>+</sup> tissue-resident memory T cells of skin. *Nat Immunol* (2013) 14:1294–301. doi: 10.1038/ni.2744
- Korn T, Kallies A. T cell responses in the central nervous system. *Nat Rev Immunol* (2017) 17:179–94. doi: 10.1038/nri.2016.144
- Russo MV, McGavern DB. Immune Surveillance of the CNS following Infection and Injury. *Trends Immunol* (2015) 36:637–50. doi: 10.1016/j.it.2015.08.002
- Steinbach K, Vincenti I, Kreutzfeldt M, Page N, Muschwackh A, Wagner I, et al. Brain-resident memory T cells represent an autonomous cytotoxic barrier to viral infection. *J Exp Med* (2016) 213:1571–87. doi: 10.1084/jem.20151916
- Schenkel JM, Fraser KA, Vezys V, Masopust D. Sensing and alarm function of resident memory CD8<sup>+</sup> T cells. *Nat Immunol* (2013) 14:509–13. doi: 10.1038/ni.2568
- Merkler D, Horvath E, Bruck W, Zinkernagel RM, De La Torre JC, Pinschewer DD. “Viral déjà vu” elicits organ-specific immune disease independent of reactivity to self. *J Clin Invest* (2006) 116:1254–63. doi: 10.1172/JCI27372
- Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular Signature of CD8<sup>+</sup> T Cell Exhaustion during Chronic Viral Infection. *Immunity* (2007) 27:670–84. doi: 10.1016/j.immuni.2007.09.006
- Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* (2006) 439:682–7. doi: 10.1038/nature04444
- Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJD, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. *J Exp Med* (1998) 188:2205–13. doi: 10.1084/jem.188.12.2205
- Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment. *J Virol* (2003) 77:4911–27. doi: 10.1128/JVI.77.8.4911-4927.2003
- Utzschneider DT, Alfei F, Roelli P, Barras D, Chennupati V, Darbre S, et al. High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. *J Exp Med* (2016) 213:1819–34. doi: 10.1084/jem.20150598

## DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## ETHICS STATEMENT

Experiments were conducted in accordance with national Danish guidelines (Amendment # 1306 of November 23, 2007) regarding animal experiments as approved by the Danish Animal Experiments Inspectorate, Ministry of Justice, permission number 2015-15-0201-00623.

## AUTHOR CONTRIBUTIONS

AS, LN, JC, and AT designed the study. AS and LN performed the experiments and analyzed the data. AS, LN, JC, and AT interpreted the data. AS and AT drafted the manuscript. All authors contributed to the article and approved the submitted version.

## FUNDING

This work was supported by Scleroseforeningen (A33255 and A37864), Warwara Larsen’s Fund, the Danish Medical Research Council (7016-00234) and Faculty of Health and Medical Sciences, University of Copenhagen.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2020.595707/full#supplementary-material>

12. Shin H, Wherry EJ. CD8 T cell dysfunction during chronic viral infection. *Curr Opin Immunol* (2007) 19:408–15. doi: 10.1016/j.coi.2007.06.004
13. Chatterjee B, Deng Y, Holler A, Nunez N, Azzi T, Vanoaica LD, et al. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo. *PLoS Pathog* (2019) 15:1–27. doi: 10.1371/journal.ppat.1007748
14. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. *Nat Immunol* (2009) 10:29–37. doi: 10.1038/ni.1679
15. Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, et al. CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. *PLoS Pathog* (2015) 11:1–21. doi: 10.1371/journal.ppat.1005177
16. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. *Curr Opin Immunol* (2010) 22:223–30. doi: 10.1016/j.coi.2010.02.005
17. Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. *Virology* (2015) 479–480:180–93. doi: 10.1016/j.virol.2014.12.033
18. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. *Nat Commun* (2016) 7:1–9. doi: 10.1038/ncomms10501
19. Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, et al. Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection. *Science* (80-) (2012) 338:1220–5. doi: 10.1126/science.1229620
20. Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, et al. Structure and interactions of the human programmed cell death 1 receptor. *J Biol Chem* (2013) 288:11771–85. doi: 10.1074/jbc.M112.448126
21. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nat Immunol* (2001) 2:261–8. doi: 10.1038/85330
22. Shwetank, Frost EL, Mockus TE, Ren HM, Toprak M, Lauver MD, et al. PD-1 dynamically regulates inflammation and development of brain-resident memory CD8 T cells during persistent viral encephalitis. *Front Immunol* (2019) 10:783. doi: 10.3389/fimmu.2019.00783
23. Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, et al. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. *Annu Rev Med* (2018) 69:301–18. doi: 10.1146/annurev-med-012017-043208
24. Duncan DS, Miller SD. CNS expression of B7-H1 regulates pro-inflammatory cytokine production and alters severity of Theiler's virus-induced demyelinating disease. *PLoS One* (2011) 6:1–11. doi: 10.1371/journal.pone.0018548
25. Scheiner B, Bailey SL, Shin T, Chen L, Miller SD. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T cell responses in EAE. *Eur J Immunol* (2009) 38:2706–17. doi: 10.1002/eji.200838137
26. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. *Proc Natl Acad Sci U S A* (2004) 101:10691–6. doi: 10.1073/pnas.0307252101
27. Prasad S, Hu S, Sheng WS, Chauhan P, Singh A, Lokensgard JR. The PD-1: PD-L1 pathway promotes development of brain-resident memory T cells following acute viral encephalitis. *J Neuroinflamm* (2017) 14:1–13. doi: 10.1186/s12974-017-0860-3
28. Schachtele SJ, Hu S, Sheng WS, Mutnal MB, Lokensgard JR. Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1. *Glia* (2014) 62:1582–94. doi: 10.1002/glia.22701
29. Phares TW, Ramakrishna C, Parra GI, Epstein A, Chen L, Atkinson R, et al. Target-Dependent B7-H1 Regulation Contributes to Clearance of Central Nervous System Infection and Dampens Morbidity. *J Immunol* (2009) 182:5430–8. doi: 10.4049/jimmunol.0803557
30. Magnus T, Schreiner B, Korn T, Jack C, Guo H, Antel J, et al. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: Implications for immune responses and autoimmunity in the CNS. *J Neurosci* (2005) 25:2537–46. doi: 10.1523/JNEUROSCI.4794-04.2005
31. Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, et al. The epigenetic landscape of T cell exhaustion. *Science* (80-) (2016) 354:1165–9. doi: 10.1126/science.aae0491
32. Youngblood B, Oestreich KJ, Ha SJ, Duraiswamy J, Akondy RS, West EE, et al. Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells. *Immunity* (2011) 35:400–12. doi: 10.1016/j.immuni.2011.06.015
33. Shwetank, Abdelsamed HA, Frost EL, Schmitz HM, Mockus TE, Youngblood BA, et al. Maintenance of PD-1 on brain-resident memory CD8 T cells is antigen independent. *Immunol Cell Biol* (2017) 95:953–9. doi: 10.1038/icb.2017.62
34. Bengsch B, Ohtani T, Khan O, Setty M, Manne S, O'Brien S, et al. Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. *Immunity* (2018) 48:1029–45.e5. doi: 10.1016/j.immuni.2018.04.026
35. Ahn E, Youngblood B, Lee J, Lee J, Sarkar S, Ahmed R. Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. *J Virol* (2016) 90:8934–46. doi: 10.1128/jvi.00798-16
36. Prasad S, Hu S, Sheng WS, Chauhan P, Lokensgard JR. Reactive glia promote development of CD103+CD69+ CD8+ T-cells through programmed cell death-ligand 1 (PD-L1). *Immun Inflammation Dis* (2018) 6:332–44. doi: 10.1002/iid3.221
37. Schöller AS, Fonnes M, Nazerai L, Christensen JP, Thomsen AR. Local antigen encounter is essential for establishing persistent CD8+ T-cell memory in the CNS. *Front Immunol* (2019) 10:351. doi: 10.3389/fimmu.2019.00351
38. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, Zhou D, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: Implications for their use as vaccines. *Blood* (2007) 110:1916–23. doi: 10.1182/blood-2007-02-062117
39. Bassett JD, Yang TC, Bernard D, Millar JB, Swift SL, McGray AJR, et al. CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells. *Blood* (2011) 117:1146–55. doi: 10.1182/blood-2010-03-272336
40. Holst PJ, Bartholdy C, Stryhn A, Thomsen AR, Christensen JP. Rapid and sustained CD4+ T-cell-independent immunity from adenovirus-encoded vaccine antigens. *J Gen Virol* (2007) 88:1708–16. doi: 10.1099/vir.0.82727-0
41. Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, Christensen JP. MHC Class II-Associated Invariant Chain Linkage of Antigen Dramatically Improves Cell-Mediated Immunity Induced by Adenovirus Vaccines. *J Immunol* (2008) 180:3339–46. doi: 10.4049/jimmunol.180.5.3339
42. Pinschewer DD, Brinkmann V, Merkler D. Impact of sphingosine 1-phosphate modulation on immune outcomes. *Neurology* (2011) 76:15–9. doi: 10.1212/WNL.0b013e31820d9596
43. Blanc CA, Rosen H, Lane TE. FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination. *J Neuroinflamm* (2014) 11:1–12. doi: 10.1186/s12974-014-0138-y
44. Smolders J, Heutinck KM, Franssen NL, Remmerswaal EBM, Hombrink P, ten Berge IJM, et al. Tissue-resident memory T cells populate the human brain. *Nat Commun* (2018) 9:1–14. doi: 10.1038/s41467-018-07053-9
45. Wakim LM, Woodward-Davis A, Bevan MJ. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. *Proc Natl Acad Sci U S A* (2010) 107:17872–9. doi: 10.1073/pnas.1010201107
46. Gebhardt T, Palendira U, Tschärke DC, Bedoui S. Tissue-resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance. *Immunol Rev* (2018) 283:54–76. doi: 10.1111/imr.12650
47. Fuller MJ, Khanolkar A, Tebo AE, Zajac AJ. Maintenance, Loss, and Resurgence of T Cell Responses During Acute, Protracted, and Chronic Viral Infections. *J Immunol* (2004) 172:4204–14. doi: 10.4049/jimmunol.172.7.4204
48. Jones AT, Federspiel B, Ellies LG, Williams MJ, Burgener R, Duronio V, et al. Characterization of the activation-associated isoform of CD43 on murine T lymphocytes. *J Immunol* (1994) 153:3426–39.
49. Kantzer C G, Boutin C, Herzig ID, Wittwer C, Reiß S, Tiveron MC, et al. Anti-ACSA-2 defines a novel monoclonal antibody for prospective isolation of

- living neonatal and adult astrocytes. *Glia* (2017) 65:990–1004. doi: 10.1002/glia.23140
50. Duchala CS, Asotra K, Macklin WB. Expression of cell surface markers and myelin proteins in cultured oligodendrocytes from neonatal brain of rat and mouse: A comparative study. *Dev Neurosci* (1995) 17:70–80. doi: 10.1159/000111276
  51. Kolls JK, Habetz S, Shean MK, Vazquez C, Brown JA, Lei D, et al. IFN- $\gamma$  and CD8<sup>+</sup> T cells restore host defenses against *Pneumocystis carinii* in mice depleted of CD4<sup>+</sup> T cells. *J Immunol* (1999) 162:2890–4.
  52. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. *Proc Natl Acad Sci* (2012) 109:7037–42. doi: 10.1073/pnas.1202288109
  53. Mackay LK, Wynne-Jones E, Freestone D, Pellicci DG, Mielke LA, Newman DM, et al. T-box Transcription Factors Combine with the Cytokines TGF- $\beta$  and IL-15 to Control Tissue-Resident Memory T Cell Fate. *Immunity* (2015) 43:1101–11. doi: 10.1016/j.immuni.2015.11.008
  54. Kaech SM, Cui W. Transcriptional control of effector and memory CD8<sup>+</sup> T cell differentiation. *Nat Rev Immunol* (2012) 12:749–61. doi: 10.1038/nri3307
  55. Mackay LK, Kallies A. Transcriptional Regulation of Tissue-Resident Lymphocytes. *Trends Immunol* (2017) 38:94–103. doi: 10.1016/j.it.2016.11.004
  56. Christensen JE, Andreassen S, Christensen JP, Thomsen AR. CD11b expression as a marker to distinguish between recently activated effector CD8<sup>+</sup> T cells and memory cells. *Int Immunol* (2001) 13:593–600. doi: 10.1093/intimm/13.4.593
  57. Prasad S, Lokensgard JR. Brain-Resident T Cells Following Viral Infection. *Viral Immunol* (2019) 32:48–54. doi: 10.1089/vim.2018.0084
  58. Cheuk S, Schlums H, Gallais Sérézal I, Martini E, Chiang SC, Marquardt N, et al. CD49a Expression Defines Tissue-Resident CD8<sup>+</sup> T Cells Poised for Cytotoxic Function in Human Skin. *Immunity* (2017) 46:287–300. doi: 10.1016/j.immuni.2017.01.009
  59. Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, et al. IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. *J Exp Med* (2017) 214:1567–80. doi: 10.1084/jem.20162115
  60. Boldison J, Chu CJ, Copland DA, Lait PJP, Khera TK, Dick AD, et al. Tissue-Resident Exhausted Effector Memory CD8<sup>+</sup> T Cells Accumulate in the Retina during Chronic Experimental Autoimmune Uveoretinitis. *J Immunol* (2014) 192:4541–50. doi: 10.4049/jimmunol.1301390
  61. Casey KA, Fraser KA, Schenkel JM, Moran A, Abt MC, Beura LK, et al. Antigen-Independent Differentiation and Maintenance of Effector-like Resident Memory T Cells in Tissues. *J Immunol* (2012) 188:4866–75. doi: 10.4049/jimmunol.1200402
  62. Hofmann M, Pircher H. E-cadherin promotes accumulation of a unique memory CD8 T-cell population in murine salivary glands. *Proc Natl Acad Sci U S A* (2011) 108:16741–6. doi: 10.1073/pnas.1107200108
  63. Gouttefangeas C, Mansur I, Schmid M, Dastot H, Gélén C, Mahouy G, et al. The CD39 molecule defines distinct cytotoxic subsets within alloactivated human CD8<sup>+</sup>-positive cells. *Eur J Immunol* (1992) 22:2681–5. doi: 10.1002/eji.1830221031
  64. Tóth I, Le AQ, Hartjen P, Thomssen A, Matzat V, Lehmann C, et al. Decreased frequency of CD73<sup>+</sup> CD8<sup>+</sup> T cells of HIV-infected patients correlates with immune activation and T cell exhaustion. *J Leukoc Biol* (2013) 94:551–61. doi: 10.1189/jlb.0113018
  65. Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. *Cancer Res* (2015) 75:296–305. doi: 10.1158/0008-5472.CAN-14-2277
  66. Macintyre AN, Finlay D, Preston G, Sinclair LV, Waugh CM, Tamas P, et al. Protein Kinase B Controls Transcriptional Programs that Direct Cytotoxic T Cell Fate but Is Dispensable for T Cell Metabolism. *Immunity* (2011) 34:224–36. doi: 10.1016/j.immuni.2011.01.012
  67. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. *Nature* (2009) 460:108–12. doi: 10.1038/nature08155
  68. Kim EH, Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. *Front Immunol* (2013) 4:20. doi: 10.3389/fimmu.2013.00020
  69. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The development and immunosuppressive functions of CD4<sup>+</sup> CD25<sup>+</sup> FoxP3<sup>+</sup> regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. *Front Immunol* (2012) 3:190. doi: 10.3389/fimmu.2012.00190
  70. Cekic C, Linden J. Adenosine A2A receptors intrinsically regulate CD8<sup>+</sup> T cells in the tumor microenvironment. *Cancer Res* (2014) 74:7239–49. doi: 10.1158/0008-5472.CAN-13-3581
  71. Bono MR, Fernández D, Flores-Santibáñez F, Roseblatt M, Sauma D. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression. *FEBS Lett* (2015) 589:3454–60. doi: 10.1016/j.febslet.2015.07.027
  72. Utzschneider DT, Legat A, Fuentes Marraco SA, Carrié L, Luescher I, Speiser DE, et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. *Nat Immunol* (2013) 14:603–10. doi: 10.1038/ni.2606
  73. Wakim LM, Woodward-Davis A, Liu R, Hu Y, Villadangos J, Smyth G, et al. The Molecular Signature of Tissue Resident Memory CD8 T Cells Isolated from the Brain. *J Immunol* (2012) 189:3462–71. doi: 10.4049/jimmunol.1201305

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Schöller, Nazerai, Christensen and Thomsen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.